Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis president joins Qu Biologics

Robert Pelzer is appointed board member at immunotherapy specialists

Qu Biologics Robert Pelzer

Qu Biologics has appointed former president of Novartis' US operations Robert Pelzer to its board of directors.

Pelzer was appointed president of Novartis Corporation in 2008, holding responsibility for Novartis' operations in North America.

He was previously global general counsel and head of legal services for Novartis at a corporate level.

Before joining Novartis in 2002, he spent several years at DuPont Pharmaceuticals, serving as general counsel and senior VP.

His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease.

“Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be invaluable to Qu Biologics during this important stage of our growth and development,” said CEO of Qu Biologics Dr Hal Gunn, who also noted that Pelzer will help develop relationships with potential pharma partners.

18th June 2013

From: Research

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
fox&cat

Fox&cat is an award-winning healthcare communications agency which creates inspirational campaigns and programmes that exceed expectations. Priding itself on delivering...

Latest intelligence

New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....